{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schaffrath A"],"funding":["Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)","Deutsche Forschungsgemeinschaft","Deutsche Forschungsgemeinschaft (German Research Foundation)","Else Kröner-Fresenius-Stiftung","Parkinson’s Foundation","Köln Fortune Programme, Faculty of Medicine, University of Cologne","Parkinson's Foundation (Parkinson's Foundation, Inc.)"],"pagination":["14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9895074"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson's disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive and specific assays. Recent studies suggest that α-synuclein aggregates may be shed into stool. We used surface-based fluorescence intensity distribution analysis (sFIDA) to detect and quantify single particles of α-synuclein aggregates in stool of 94 PD patients, 72 isolated rapid eye movement sleep behavior disorder (iRBD) patients, and 51 healthy controls. We measured significantly elevated concentrations of α-synuclein aggregates in stool of iRBD patients versus those of controls (p = 0.024) or PD patients (p < 0.001). Our results show that α-synuclein aggregates are excreted in stool and can be measured using the sFIDA assay, which could support the diagnosis of prodromal synucleinopathies."],"journal":["NPJ Parkinson's disease"],"pubmed_title":["Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool."],"pmcid":["PMC9895074"],"funding_grant_id":["431549029","2019_EKES.02","PF-IMP-2022"],"pubmed_authors":["Schleyken S","Jergas H","Bannach O","Fink GR","Willbold D","Willbold J","Bujnicki T","Pils M","Barbe MT","Tamguney G","Ozduzenciler P","Sommerauer M","Seger A","Schaffrath A","Blomeke L","Cousin A"],"additional_accession":[]},"is_claimable":false,"name":"Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool.","description":"Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson's disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates in body fluids is challenging, and requires highly sensitive and specific assays. Recent studies suggest that α-synuclein aggregates may be shed into stool. We used surface-based fluorescence intensity distribution analysis (sFIDA) to detect and quantify single particles of α-synuclein aggregates in stool of 94 PD patients, 72 isolated rapid eye movement sleep behavior disorder (iRBD) patients, and 51 healthy controls. We measured significantly elevated concentrations of α-synuclein aggregates in stool of iRBD patients versus those of controls (p = 0.024) or PD patients (p < 0.001). Our results show that α-synuclein aggregates are excreted in stool and can be measured using the sFIDA assay, which could support the diagnosis of prodromal synucleinopathies.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-03-17T15:56:26.7Z","creation":"2025-05-29T19:44:05.696Z"},"accession":"S-EPMC9895074","cross_references":{"pubmed":["36732520"],"doi":["10.1038/s41531-023-00458-4"]}}